January 2021
-
Media ReleaseNovartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.Full year net sales from continuing operations1 up 3% (cc2, +3% USD): Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc), Ilaris…
-
Media ReleaseSandoz officially certified as Global Top Employer 2021Top Employers Institute recognizes Sandoz for its exceptional employee offerings globally Third such annual certification for Sandoz underlines ongoing commitment to attract and keep best talent by…
October 2020
-
Media ReleaseNovartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.Q3 net sales from continuing operations1were in line with prior year (cc2, +1% USD): Growth drivers included Entresto USD 632 million (+45% cc), Zolgensma USD 291 million (+79% cc), Cosentyx USD 1…
-
Media ReleaseSandoz appoints new Board representative to global AMR Industry AllianceDominic De Souza, global head of Anti-Infectives sustainability and AMR program, appointed to represent Sandoz on AMR Industry Alliance Alliance brings together approximately 100 life science…
-
Media ReleaseSandoz Donates 20 critically needed generic medicines to hospitals and dispensaries in continued support of the people of BeirutIn continued support of the people of Beirut, Lebanon impacted by the August 4 port explosion and the ongoing rebuilding efforts, Sandoz has donated 20 critically needed generic medicines through the…
-
Media ReleaseSandoz launches its first RFID-tagged critical injectable medicines with Kit Check to optimize supply chain and automate restocking in US hospitalsFirst three Sandoz medicines labeled with RFID technology will be available in US hospitals starting in October, followed by several more through Q1 2021 Sandoz and Kit Check together provide…
July 2020
-
Media ReleaseSandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in EuropeSandoz and Austrian government announce joint plans to drive long-term competitiveness of European production for key antibiotics in Europe Planned combined investment of more than EUR 150 million…
-
Media ReleaseNovartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.Due to COVID-19 first half results are more representative of underlying performance than Q2, sales growth of 6% (cc1, +3% USD) and core¹ operating income growth of 19% (cc, +14% USD): Innovative…
-
Media ReleaseSandoz launches generic antibiotic Daptomycin in US, strategically growing injectables portfolio and strengthening hospital offeringDaptomycin is an antibacterial medicine used to treat adult patients with complicated skin and skin structure infections 1 Daptomycin can be used to treat patients with MRSA or “superbug”…